Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Pharmaceutical
The Russian pharmaceutical market is gradually returning to its normal state after several weeks of a roaring demand caused by the COVID-19 pandemic in the country and associated with panic buying of certain drugs, according to recent statements by some leading local producers and analysts in the field of pharmaceutics, reports The Pharma Letter’s local correspondent. 19 May 2020
Pharmaceutical
The global coronavirus pandemic has placed an unprecedented strain on the pharmaceutical industry, with the enforcement of strict lockdown measures disrupting enrolment onto clinical trials and delaying decisions on drugs nearing approval. 14 May 2020
Generics
The Russian government plans to provide support to producers of cheap drugs, with the aim to prevent their disappearance from the domestic market, according to recent statements by representatives of some senior state officials and industry’s analysts, reports The Pharma Letter’s local correspondent. 12 May 2020
Pharmaceutical
There are around 90 vaccines being developed against COVID-19 by research teams in companies and universities across the world, with most experts predicting that an effective vaccine could become available by mid-2021. 11 May 2020
Pharmaceutical
The fallout from the COVID-19 pandemic has been challenging for many life sciences companies due to a wide range of factors including impaired access to the healthcare system, travel restrictions, new guidance from regulatory agencies, and a shift in healthcare resources to fighting the pandemic. 7 May 2020
Biotechnology
Mark Brewer, who heads up the life sciences team at UK broker and M&A advisory company, finnCap, gives an overview of some of the growth companies that are currently actively working in the fight against coronavirus in an Expert View piece. 6 May 2020
Pharmaceutical
The ongoing spread of COVID-19 in Russia is leading to shortages of drugs against orphan diseases in the local market, according to recent statements by some senior state officials of the Russian Ministry of Health and local analysts, reports The Pharma Letter’s local correspondent. 5 May 2020
Pharmaceutical
Reaching into every part of professional and personal life, the coronavirus pandemic has turned the world on its head, making old certainties seem fragile while forcing change from every corner. 1 May 2020
Pharmaceutical
At a time when most sectors on the stock markets have taken a beating, courtesy of the COVID-19 pandemic, the pharmaceutical industry has outperformed, with some Indian pharma stocks that have higher contribution to the domestic business registering a stronger performance than peers. Pharma stocks have clocked massive buying in the last 10 days, reports The Pharma Letter’s India correspondent. 1 May 2020
Biotechnology
There was a time when executives at Teva Pharmaceutical Industries thought that their product might be the third anti-calcitonin gene-related peptide (CGRP) drug to be recommended by the National Institute for Health and Care Excellence (NICE). 29 April 2020
Generics
Leading Russian drugmakers and foreign companies operating in Russia have opposed the introduction of amendments to the existing rules for registration and examination of drugs in the domestic market which create a single register of patented active ingredients in the market of Russia as well as some other post-Soviet states, reports The Pharma Letter’s local correspondent. 28 April 2020
Biotechnology
Like many companies announcing projects targeting COVID-19, German immunotherapeutics specialist BioNTech experienced a share price fillip when it announced plans for a vaccine in March. 24 April 2020
Pharmaceutical
R-Pharm, one of Russia’s leading drugmakers, plans to accelerate the development and launch of certain new drugs in the domestic market this year, paying a particular attention for those that could be recommended for the use to treat COVID-19, according to recent statements Aleksey Repik, head of the company in an interview with the Forbes Russia magazine, reports The Pharma Letter’s local correspondent. 21 April 2020
Generics
Approvals from the US Food and Drug Administration are coming in thick and fast, in what has come as a major relief for Indian pharmaceutical companies. 20 April 2020
Pharmaceutical
For World Hemophilia Day, Friday April 17, Dr Nicola Davies presents the most recent advances in the pharmaceutical management of this congenital bleeding disorder, including therapeutic interventions on the horizon. 17 April 2020
Pharmaceutical
The Russian government and representatives of some of leading drugmakers operating in the local market have confirmed they will ensure uninterrupted supplies of drugs and vaccines against COVID-19 to Russia, in anticipation of a significant increase on the number of people infected with coronavirus, according to recent statements by representatives of producers, reports The Pharma Letter’s local correspondent. 15 April 2020
Pharmaceutical
China recently issued the amended version of drug registration regulation, effective on July 1, reports The Pharma Letter’s local correspondent Wang Fangqing. 14 April 2020
Pharmaceutical
A Supplementary Protection Certificate (SPC) is an extremely valuable prize for the pharmaceutical patent owner as it extends the patent life of an authorised medicine for up to five years at a time when a successful drug is likely to be well established and at the top of its earning power. 14 April 2020
Pharmaceutical
The Russian drug manufacturers that have managed to increase sales amid the spread of coronavirus infection COVID-19, may again face shortages of raw materials for their production. 7 April 2020
Biotechnology
As the destructive power of COVID-19 skulks through the bourses of every continent, the first quarter of 2020 has delivered a punishing blow for investors in stocks of every stripe. 3 April 2020
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze